Pemphigus Vulgaris

6
Pipeline Programs
4
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

argenx
argenxBelgium - Zwijnaarde
3 programs
1
2
efgartigimod PH20 SCPhase 31 trial
efgartigimod PH20 SCPhase 31 trial
ARGX-113Phase 21 trial
Active Trials
NCT03334058Completed34Est. Oct 2020
NCT04598477Terminated183Est. Mar 2024
NCT04598451Completed222Est. Aug 2023
Genentech
GenentechCA - Oceanside
1 program
1
Mycophenolate Mofetil PlaceboPhase 31 trial
Active Trials
NCT02383589Completed135Est. Oct 2019
Sanofi
SanofiPARIS, France
1 program
1
PRN1008Phase 21 trial
Active Trials
NCT02704429Completed42Est. Jan 2020
Cabaletta Bio
Cabaletta BioPHILADELPHIA, PA
1 program
1
DSG3-CAARTPhase 1/21 trial
Active Trials
NCT04422912Recruiting40Est. Jan 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
argenxefgartigimod PH20 SC
argenxefgartigimod PH20 SC
GenentechMycophenolate Mofetil Placebo
argenxARGX-113
SanofiPRN1008
Cabaletta BioDSG3-CAART

Clinical Trials (6)

Total enrollment: 656 patients across 6 trials

NCT04598477argenxefgartigimod PH20 SC

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Start: Jul 2021Est. completion: Mar 2024183 patients
Phase 3Terminated
NCT04598451argenxefgartigimod PH20 SC

A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Start: Dec 2020Est. completion: Aug 2023222 patients
Phase 3Completed
NCT02383589GenentechMycophenolate Mofetil Placebo

A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)

Start: May 2015Est. completion: Oct 2019135 patients
Phase 3Completed
NCT03334058argenxARGX-113

A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus

Start: Oct 2017Est. completion: Oct 202034 patients
Phase 2Completed
NCT02704429SanofiPRN1008

A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris

Start: Jan 2016Est. completion: Jan 202042 patients
Phase 2Completed
NCT04422912Cabaletta BioDSG3-CAART

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Start: Sep 2020Est. completion: Jan 202940 patients
Phase 1/2Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 656 patients
4 companies competing in this space